16.30
0.00%
Close of 9 Nov 2026, in PLN
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Celon Pharma
Its shares trade on GPW under the ticker CLN.WA. It has been listed since 1 December 2016. In the fiscal year to 31 December 2025, it reported revenue of PLN 209.8m and a net loss of PLN 79.4m. At that date it held total assets of PLN 457.5m and shareholders' equity of PLN 363.2m.
Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The firm's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The firm is a subsidiary of Glatton sp z o o.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Dec 2016
- Employees
- 513
- Website
- celonpharma.com ↗
Leadership
Pay as last reported
- Mr. Robert RzeminskiChairman of the Supervisory BoardPLN 2,400
- Dr. Maciej WieczorekChairman of the Management Board, Chief Executive OfficerPLN 7.7m
- Mr. Bartosz SzalekFinancial Director, Member of the Management Board
- Ms. Malgorzata StokrockaMember of the Management Board
- Mr. Krzysztof KaczmarczykIndependent Member of the Supervisory Board
- Mr. Boguslaw GalewskiMember of the Supervisory Board
- Mr. Artur WieczorekMember of the Supervisory BoardPLN 77,518
- Ms. Urszula WieczorekMember of the Supervisory BoardPLN 47,865
- Ms. Malgorzata SiewierskaCoordinator for Communication and Investor Relations
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Celon Pharma SA focuses on generic drugs for cancer and neurological diseases with products like Bosentan Celon and Donepex.
- The company's research center develops pharmaceuticals in oncology and inflammatory diseases with strong product portfolio.
- Celon Pharma SA has a subsidiary Glatton sp z o o, providing strategic support and resources for growth.
Weaknesses
- Celon Pharma SA has only 513 employees, which may limit research and production capacity.
- The company is listed on 1 December 2016, indicating a relatively young market presence.
- Celon Pharma SA's product range includes only pills and inhalation powders like Salmex, lacking diversity.
Opportunities
- Celon Pharma SA can expand its product portfolio in metabolic disorders with drugs like Ketrel and Valzek.
- The company can leverage its subsidiary Glatton sp z o o for international market entry in Europe.
- Growing demand for generic drugs in Poland offers potential for increased market share.
Threats
- Celon Pharma SA faces competition from established pharmaceutical companies in the Health Care sector.
- The company's reliance on a limited product range may expose it to market fluctuations.
- Regulatory changes in the Polish pharmaceutical market could impact production and sales.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.